NanoViricides Inc (NYSEAMERICAN:NNVC) was the target of a significant increase in short interest in August. As of August 31st, there was short interest totalling 269,581 shares, an increase of 29.0% from the August 15th total of 208,910 shares. Based on an average daily volume of 197,664 shares, the short-interest ratio is presently 1.4 days. Currently, 0.5% of the company’s stock are short sold.
An institutional investor recently raised its position in NanoViricides stock. Renaissance Technologies LLC raised its position in NanoViricides Inc (NYSEAMERICAN:NNVC) by 67.1% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 888,372 shares of the company’s stock after acquiring an additional 356,872 shares during the quarter. Renaissance Technologies LLC owned approximately 1.29% of NanoViricides worth $391,000 at the end of the most recent reporting period.
NanoViricides stock traded up $0.01 during mid-day trading on Friday, reaching $0.33. The company’s stock had a trading volume of 64,520 shares, compared to its average volume of 136,447. NanoViricides has a 12 month low of $0.25 and a 12 month high of $1.23.
NanoViricides Company Profile
NanoViricides, Inc, a nano-biopharmaceutical company, discovers, develops, and commercializes therapeutics for the treatment of viral infections. The company is developing anti-influenza drug candidates at pre-clinical and advanced pre-clinical stage, which include two FluCide drugs, such as NV-INF-2, an oral anti-influenza drug and NV-INF-1, an injectable anti-influenza drug for H7N9, Bird Flu H5N1, and other Highly Pathogenic Influenzas; and HIVCide, an anti-human immunodeficiency virus (HIV) drug candidate that could provide functional cure for HIV/AIDS.
See Also: How a Put Option Works
Receive News & Ratings for NanoViricides Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NanoViricides and related companies with MarketBeat.com's FREE daily email newsletter.